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Abstract

Author Manuscript

Purpose of Review—Despite over a third of the world’s population being chronically infected
with Toxoplasma gondii, little is known about this largely asymptomatic phase of infection. This
stage is mediated in vivo by bradyzoites within tissue cysts. The absence of overt symptoms has
been attributed to the dormancy of bradyzoites. In this review, we reexamine the conventional view
of chronic toxoplasmosis in light of emerging evidence challenging both the nature of dormancy
and the consequences of infection in the CNS.
Recent Findings—New and emerging data reveal a previously unrecognized level of
physiological and replicative capacity of bradyzoites within tissue cysts. These findings have
emerged in the context of a reexamination of the chronic infection in the brain that correlates with
changes in neuronal architecture, neurochemistry, and behavior that suggest that the chronic
infection is not without consequence.

Author Manuscript

Summary—The emerging data driven by the development of new approaches to study the
progression of chronic toxoplasma infection reveals significant physiological and replicative
capacity for what has been viewed as a dormant state. The emergence of bradyzoite and tissue cyst
biology from what was viewed as a physiological “black box” offers exciting new areas for
investigation with direct implications on the approaches to drug development targeting this drugrefractory state. In addition, new insights from studies on the neurobiology on chronic infection
reveal a complex and dynamic interplay between the parasite, brain microenvironment, and the
immune response that results in the detente that promotes the life-long persistence of the parasite
in the host.
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Introduction
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The transmission of Toxoplasma gondii is mediated by two distinct cyst forms, the oocysts
formed and shed into the environment by the definitive feline host and the tissue cyst,
formed within and retained in all infected warm blooded animals [1]. Transmission of tissue
cysts occurs during the act of carnivory or scavenging of infected tissues. T. gondii acquired
by either form manifests as an acute infection associated with the rapid replication and
spread within the body of the host of the tachyzoite form [1, 2]. This phase of infection
within an immune competent host is typically asymptomatic as proliferating tachyzoites are
cleared with the mounting of an aggressive innate and acquired immune response. However,
unlike other infections, clearance of rapidly growing parasites fails to establish a sterile cure
as a cohort of tachyzoites differentiate into the slow growing bradyzoite form establishing
themselves within tissue cysts primarily in the CNS and muscle [1, 3]. These tissue cysts are
maintained for the life of the host, progressing in their cycle during carnivory and
completing the sexual cycle when the carnivore is a feline [1, 4].

Author Manuscript

The life-long persistence of tissue cysts and the bradyzoites they house is attributable to their
relative invisibility to immune detection, a property lost when reactivation to tachyzoites
occurs [5]. In the absence of immune function, most notably the loss of T cell immunity, as
occurs in active HIV-AIDS, reactivation of bradyzoites to tachyzoites results in unrestricted
growth [6]. Untreated active toxoplasmosis typically manifests as toxoplasmic encephalitis,
on account of the CNS being a primary target for tissue cyst formation. This infection is
lethal in the context of active HIV-AIDS [7]. Given the high seroprevalence of toxoplasma
infections in the general human population that approaches 30 % worldwide [8], life-long
persistence of the agent within tissue cysts represents a potential source of active infection
following immune suppression [7]. In spite of its critical status in the pathogenesis of
toxoplasma infections, surprisingly, little work has been done into dissecting bradyzoite and
tissue cyst biology.

Author Manuscript

Much of what we know about bradyzoite biology comes from a combination of detailed
morphological studies [3, 9–13] which reveal the organization of tissue cysts in vivo but
offer little information on bradyzoite physiology. In contrast, cell culture-based systems have
focused on the critical transition from tachyzoites to bradyzoites but fail to adequately
address progression once in the chronic phase [14–16]. Studies focused on the
transcriptomes of tissue cysts (both in culture and in vivo) by necessity [17, 18•] presented a
weighted average that masks the behavior of individual tissue cysts and by extension that of
individual bradyzoites within them. The recurring differences, in cyst burden and size, were
largely attributed to variations with the host response [19, 20] with little consideration to the
fact that bradyzoites themselves may be considerably more dynamic than has been
previously imagined [21••].
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Virtually, all of the functional studies to date, including those assessing the effectiveness of
drugs, have used the tissue cyst (their numbers and size) as the metric. Inherent in defining
the tissue cyst rather than the individual bradyzoite within it as the “unit” of the chronic
phase is the assumption that cysts are largely equivalent and the bradyzoites within them
uniform with regard to their physiology. The first systematic analysis of bradyzoite
dynamics within cysts, recently published by our group [21••], directly challenges this
notion necessitating a reassessment of how we approach understanding chronic
toxoplasmosis and the development of drugs against this recalcitrant life cycle stage.

Organization of the In Vivo Tissue Cyst

Author Manuscript

The tissue cyst stage of T. gondii is defined by the elevated level of glycosylation and the
transformation of the parasitophorous vacuole membrane (PVM) into the tissue cyst wall
[22]. The cyst wall is 250–500 nm in thickness and is formed from the PVM with a dense
outer layer sandwiched between the PVM and a more amorphous inner sponge-like layer
[23]. The tachyzoite intravacuolar network is itself transformed into a meshwork of
glycosylated proteins and glycolipids which form a filamentous meshwork that is connected
to the tissue cyst wall [23]. The relative volume occupied by the bradyzoites and this matrix
varies between cysts [11, 23, 24] and likely contributes to the different hydrodynamic
densities in Percoll gradients that paradoxically shift from more dense to less dense with the
progression of the chronic phase [21••].

Author Manuscript

The cyst wall, clearly evident by electron microscopy, can also be visualized by fluorescence
microscopy using labeled lectins. Glycosylation in both tachyzoites and tissue cysts is
evident from spatial distribution of lectin reactivity [25–28]. Lectins binds their target
glycans with high affinity and specificity [29]. The most prominent staining pattern is that of
the tissue cyst wall using Dolichos lectin (DBA; recognizing terminal GalNAc) (Fig. 1) [27,
30, 31]. The primary target being glycosylated with GalNAc, designated TgCST1 [32••],
was identified by the Weiss group as a high molecular weight mucin that is expressed both
in tachyzoite vacuoles and tissue cysts, but only substantially glycosylated in the tissue cyst
form [32••]. Importantly, TgCST1 plays an important structural role as knockout of this gene
results in extremely fragile cysts that are susceptible to clearance [32••]. Of note, recent
work from the Weiss laboratory has established that two distinct parasite-encoded
ppGalNAc-Ts glycosyltransferases glycosylate TgCST1 sequentially and that this
modification is critical for the structural rigidity of the cyst wall [33].

Author Manuscript

Insights into machinery associated with glycosylation emerge from the targeted disruption of
a nucleotide sugar transporter TgNST1 [34•]. Loss of this transporter, the substrate profile of
which was confirmed experimentally, established that the glycosylation of the cyst wall is
critical for the persistence of tissue cysts in vivo, despite the absence of any notable defect
for tachyzoites [34•]. Another important recent development has been the use of unnatural
sugars that can be chemically modified as tracers to identify novel glycoproteins in the
parasite without the restrictions imposed by lectin reactivity [35•]. Such approaches can be
applied to both tachyzoites and bradyzoites to establish glycoproteomes in both life cycle
stages to better define how glycosylation may impact each of these life cycle stages [35•].
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Examination of the major glycosylation pathways in toxoplasma reveals that the genes
required to add complex N-linked sugars to proteins are incomplete [36]. In addition, our
analysis of the genome fails to reveal any genes required for the synthesis or transfer of
sialic acid (Datta and Sinai unpublished). Yet, lectins directed at complex N-linked sugars
and sialic acid robustly label tissue cysts suggesting that toxoplasma may actively scavenge
these sugars from the host cell as a potential mechanism of immune evasion as has been
proposed [37, 38].

Author Manuscript

Carbohydrate metabolism plays another vital role in bradyzoite biology as evidenced by the
earliest electron microscopic studies on tissue cysts in vivo [9, 11, 24], which revealed that
bradyzoites accumulate amylopectin-like carbohydrate [39, 40]. Amylopectin is a plant
glucose storage polymer (composed of α1,4-glucose residues with α1,6 linked branch
points) [41] which has been believed to serve as a ready source of glucose (for energy and
biosynthesis) upon transmission of cyst to a new host following carnivory [39, 40]. The
distribution of amylopectin visualized using Schiff staining (Fig. 1) and electron microscopy
[9] appears to be non-uniform within encysted bradyzoites. Tonkin and colleagues recently
demonstrated that the Ca2+-dependent protein kinase TgCDPK2 is a key regulator of
amylopectin metabolism [42••]. Notably, they identified enzymes involved in T. gondii
amylopectin metabolism that are phosphorylated by TgCDPK2 [42••]. When they ablated
TgCDPK2, they found massive accumulations of amylopectin in tachyzoites which are
tolerated [42••]. In contrast, the exaggerated accumulation of amylopectin in bradyzoites
leads to bradyzoite death [42••]. This strongly suggests that amylopectin levels are tightly
regulated to ensure homeostasis within the bradyzoite making this pathway a potential target
for drug development.

Author Manuscript

Dynamics of Tissue Cyst Burden and Size in Chronic Infection
Most of our knowledge of the chronic phase of toxoplasma infection comes from the murine
infection and has focused on tissue cysts in the brain. In reality, tissue cysts form in other
tissues as well, most notably in muscle and other organs [43]. Tissue cysts in muscle are an
important source of infection of humans from the consumption of raw or undercooked meat
making it among the most prevalent food borne infections in the USA [44]. Experimental
studies on chronic toxoplasmosis in muscle are limited [45] although the recent development
of specific skeletal muscle-based infection systems will undoubtedly accelerate this work
[46–48].

Author Manuscript

The focus on chronic toxoplasmosis in the brain stems from the fact that in addition to being
the primary site of tissue cyst formation, it is also the tissue site where the reactivation of
cysts drives toxoplasmic encephalitis in the context of immune suppression [6, 7]. On a
more practical note, the brain is easily recovered intact for histological studies and easily
homogenized while maintaining the integrity of tissue cysts which can be quantified
microscopically or purified using Percoll gradients as originally developed [49] and
subsequently refined [21••]. Studies, to establish the tissue cyst burden in rodents, both mice
and rats, have been reviewed in detail [50, 51••]. Of note, tissue cyst burdens can vary
significantly, with these differences impacted by the vertebrate host, host strain, as well as
the toxoplasma strain being used [24, 51••]. This variability appears to be intrinsic as seen
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with our experience using the Type II ME49 strain, serially passaged by i.p. injection of
tissue cysts of infected brain homogenates in inbred female CBA/J mice [21••]. We found
that, in 99 independent tissue cyst purifications from mouse brains, the average cyst burden
per mouse could range from under 500 to close to 15,000 cysts [21••]. Cyst numbers,
particularly at later time points, can be the result of reactivation mediated re-seeding in
addition to the cysts established at the onset of the chronic infection. This does not appear to
be the case in rats, where cyst rupture without reactivation occurred frequently [51••] or in
CBA/J mice where the loss of a cyst was essentially balanced by its apparent replacement,
implying that vast majority of bradyzoites within the cyst were cleared [21••]. This
equilibrium appears to be responsible for the average cyst burden remaining relatively stable
across the 5 time points tested (weeks 3, 4, 5, 6, and 8 post-infection) [21••].

Author Manuscript

The size of tissue cysts, measured in situ [11, 51••, 52], in homogenized brain tissues [51••,
53, 54] and following purification in Percoll gradients [21••] has been shown to cover a large
range from 20 to over 100 microns in diameter. Of note, in rats, tissue cysts rarely reach a
diameter of 70 microns, and despite variability between toxoplasma strains, no clear pattern
is observed [51••]. These distributions varied somewhat based on the specimens being
measured with measurements from histological and electron microscopy tending to be
smaller than that seen for specimens measured in brain homogenates and following tissue
cyst purification.

Bradyzoite Replication and Growth Patterns Within Tissue Cysts During
Chronic Infection
Author Manuscript
Author Manuscript

The fact that tissue cysts exhibit heterogeneity in their size suggests that they are dynamic
growing entities despite being considered largely dormant and metabolically inert. If growth
is indeed occurring, understanding the behavior of individual bradyzoites within the tissue
cyst becomes crucial. In the course of imaging Percoll purified tissue cysts, we noted that
bradyzoites nuclei stained with DAPI or Hoescht dye presented as discrete entities in optical
sections. We therefore developed a unique imaging protocol and software, BradyCount 1.0
[21••] to directly enumerate nuclear cross-sections and by extension the number of
bradyzoites within the widest optical section (diameter) of the tissue cyst. The development
of BradyCount 1.0 and its implementation revealed that while in general larger tissue cysts
contained more bradyzoites, this rule did not always hold [21••]. We therefore developed the
concept of the “packing density” [21••] which quantified the number of bradyzoites within
the imaged volume as a way to normalize for tissue cyst size. Interestingly, the relationship
between tissue cyst size and the packing density was found to be an inverse one [21••]. As a
result, larger tissue cysts contain, in general, proportionately fewer parasites and were
typically less densely packed, i.e., they contained more matrix between the bradyzoites
[21••]. The implication of this finding is significant as it conclusively establishes that tissue
cyst size is not defined by bradyzoite replication. Rather, tissue cysts must expand in order
for bradyzoites to have the space to replicate into [21••]. Thus, shifts in the packing density
can be used as an indicator of the recency of bradyzoite replication within the tissue cyst.
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The very notion that bradyzoites can replicate has been the matter of some debate with a
suggestion that should replication occur within a cyst, it must be due to a bradyzoite
reverting to tachyzoite for the purpose of dividing [55]. In order to capture bradyzoite
replication and establish if there were any patterns in replication, we labeled purified tissue
cysts with an antibody against the inner membrane complex (IMC) component TgIMC3
[21••]. This protein has the added distinction of being more abundant in the developing
daughter scaffolds and in recently emerged parasites relative to the gravid mother or other
more mature parasites [56]. Furthermore, the Gubbels group established that TgIMC3 levels
in the mother decrease over time unless a fresh round of replication is initiated [56] (Fig. 2).
This provides for an internal marker of the recency of replication as “younger parasites”
label more brightly for TgIMC3 than “aged” organisms. When examining tissue cysts for
evidence of bradyzoite replication, we were able to capture evidence for replication at all
time points tested [21••]. Somewhat surprisingly, distinct patterns of replication within tissue
cysts emerged as well [21••]. As seen in Fig. 2, evidence of sporadic and clustered and even
completely synchronized replication were all observed. The frequent detection of clustered
replication that can extend to synchronous replication (a feature of tachyzoite replication
within a vacuole) within a tissue cyst argues for a high level of coordination and signaling
among bradyzoites within a cyst. Furthermore, this suggests that bradyzoites within a tissue
cyst are heterogenous and not monolithic physiological entities [21••] as they have been
assumed to be.

Author Manuscript
Author Manuscript

The likelihood of capturing replicating parasites was found to vary depending on the specific
state of the infection [21••]. In contrast to tachyzoites within a vacuole, bradyzoites within
tissue cysts are heterogenous with regard to their replicative potential and physiology [21••].
This greatly complicates the dissection of the chronic phase even though it progresses
toward dormancy [21••]; its path to this state appears to be opportunistic and exhibits
oscillatory behavior [21••] with a pattern suggestive of punctuated and potentially cyclical
growth profiles evident both at the level of individual bradyzoites within tissue cysts at the
population as a whole [21••]. The development of tools to address the behavior of individual
bradyzoites within cysts such as BradyCount 1.0 together with ongoing development
permitting quantitative measurement of other structural and physiological outputs
(BradyCount 2.0, Patwardhan and Sinai, in progress) will greatly expand the range of
measurable activities to gain new insights into bradyzoite biology. Given the nature of these
studies where we are constrained by practical limitations regarding the amount of data that
can be acquired, we are developing data-driven computational models to better understand
the complex and understudied progression of chronic toxoplasmosis (Patwardhan and Sinai,
in progress). The heterogeneity in bradyzoite replication and other physiological parameters
[21••] suggests an opportunistic phenomenon that is not substantially affected by the events
preceding it. Rather the behavior of a given bradyzoite within a tissue cyst or a population of
tissue cysts within an animal is dominated by the specific physiological state (or distribution
of physiological states—if examining the population) at the time of capture. This structure is
less reliant on memory and lends itself to a Markov Chain model. Such models will be of
great value to establish the mechanisms of both drug susceptibility and inherent resistance
(see below).
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How the dynamics of the chronic infection influences the host is as fascinating a question as
to how the host status influences the progression of the chronic phase within the host. The
first insights into how the presence of a chronic infection within the brain impacts gene
expression in the brain has emerged from a deep sequencing RNA Seq study from the Knoll
laboratory [18•]. Using the depth of RNA Seq and simultaneously profiling both the host
and parasite transcriptomes, they establish that despite the absence of any symptoms or other
evidence of the presence of the parasite dramatic changes in the expression of genes,
including those involved in inflammation and immune responses, are observed [18•].
Notably, on the parasite side of the equation, expression of genes associated with an active
cell cycle indicates that our notions of dormancy need to be reexamined [18•]. Thus, as
regards the chronic infection in the brain, a dynamic picture emerges that is defined by
bidirectional effects between the parasite and the host. Exciting new findings in the area are
emerging against the backdrop of understanding the neurobiology of chronic infection.

Author Manuscript

Emerging Insights into Neurobiology of Chronic Toxoplasma Infection
With its long-term, potentially lifelong residence in the brains of healthy individuals and
animals without any significant clinical consequence, chronic toxoplasma infection has been
viewed as a benign condition. This absence of overt symptomology has contributed to the
view that tissue cysts and the bradyzoites they house are dormant entities.

Author Manuscript

Recent developments in neurology, behavior, and neuroscience directly challenge the notion
that chronic toxoplasma infections are without consequence. An emerging body of evidence
suggests that the presence of an established chronic infection may contribute to the
pathogenesis of diverse neurological conditions including schizophrenia [57, 58], epilepsy
[59], and neurodegenerative conditions [60–62]. These studies and their impact on our
understanding of chronic toxoplasmosis in human disease are reviewed elsewhere [57, 59,
60, 62]. In addition, evidence from rodent studies suggests that the chronic toxoplasmosis
results in the modulation of the host’s behavior (reviewed in [63, 64]). These studies which
have received considerable traction in the popular press are also discussed in several recent
reviews and may have parallels in affecting human behavior as well [65].

Author Manuscript

The diverse spectrum of neurological and behavioral changes suggests that chronic
toxoplasma infection in the brain does in fact manifest changes reinforcing the notion that
these parasites are not truly dormant or latent. Recent studies have now begun to unveil the
potential mechanistic insights into the neurobiology of chronic toxoplasmosis. These
findings represent the first meaningful mechanistic steps into this complex interdisciplinary
area that promises to be fertile area for investigation. As a cautionary note, care must be
taken to try and untangle the effects that are a direct consequence of the parasite from those
that are driven by persistent low level inflammation in the infected brain [18•, 66].
The spectrum of neurological and behavioral changes associated with chronic toxoplasmosis
would suggest that the spatial distribution of cysts (which may number in the thousands, but
still represent a miniscule number relative to the cellularity of the brain) may govern the
phenotypic consequence [63]. While some mapping studies suggested the concentration of
cysts in the amygdala [67] and hippocampus [68], others failed to find a strong association
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for this or any other site [51••, 69–71]. Some controversy also exists with regard to the
specific cells within the brain being infected and able to house developing cysts. While there
is agreement that neurons are likely to be the primary host cell of relevance [72–74],
infection of microglia and astrocytes [73, 74] may also contribute as potential sites for tissue
cyst formation.
The first studies on the neurochemistry of chronic toxoplasmosis are now emerging and
reveal that the presence of the parasite drives changes in the levels of neurotransmitters, their
precursors, and metabolites. Among the potential direct mechanisms for the modulation of
neuronal action is the injection of primarily rhoptry derived host effector proteins (see
reviewed in [75]) into both cells that the parasites invade as well as cells they interact with
without invading [76, 77]. In this way, the parasite can directly influence not only the cell it
infects but others in their vicinity.

Author Manuscript

The perturbation of dopamine, a neurotransmitter associated with several neurodegenerative
and psychiatric conditions [78], is intriguing given that toxoplasma encodes and expresses a
secreted tyrosine hydroxylase, a key enzyme in dopamine metabolism [79•, 80]. This
presents the potential for direct manipulation of infected neurons as infected neurons release
3-fold higher levels of dopamine upon stimulation [80].

Author Manuscript

The effect of toxoplasma infection extends to gamma aminobutyric acid (GABA) synapses
and signaling. GABA is a metabolite used by the parasite and is also an inhibitory
neurotransmitter important in epilepsy. The Blader laboratory showed that, in the course of
T. gondii infection, the redistribution (but not change in levels of) of synaptic glutamic acid
decarboxylase 67 (GAD67) is associated with the development of seizures [81•]. Notably,
the duration and severity of seizures triggered by GABA agonists were dependent on the
infecting parasite strain arguing against a generalized effect caused by infection or
inflammation [81•].

Author Manuscript

Toxoplasma effectively disrupts glutamate homeostasis in the infected brain [82••]. This is
achieved by the selective downregulation of the primary astrocyte glutamate transporter
GLT1 [82••]. Astrocytes serve as a critical buffer to clear extracellular glutamate which is
neurotoxic and drives changes in neuronal architecture and morphology that interfere with
efficient neuronal function [83]. The Wilson group, in a recent study, functionally
demonstrated using microdialysis of the murine frontal cortex that levels of free glutamate
were higher in the infected brain over the course of infection [82••]. While the specific
molecular mechanism and parasite are not known, the finding that neuronal dysregulation in
chronic toxoplasma infections can be driven by an effect on astrocyte functions reveals that
this dysregulation is as sophisticated as it is complex.
Adding to the complexity of the pathogen-host relationship in the brain is the progression of
the host immune response during the course of the infection (reviewed in [84]) which is
beyond the scope of the current article.
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Therapeutic Targeting of Chronic Toxoplasma Infections
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Virtually, all studies to date to examine the effects of drugs against chronic toxoplasma
infections have used the elimination of tissue cysts as the primary metric for efficacy. This is
a relatively crude measure as it does not address the effect on the level of individual
bradyzoites, their organization within cysts, and by extension their physiological state/
replication potential. Given the heterogeneity of bradyzoites within tissue cysts and the
diversity of tissue cysts within the infected brain [21••], the dissection of drug effects needs
to be achieved at the level of bradyzoites. The imaging approached provided by BradyCount
1.0 allows for the direct enumeration of bradyzoites within cysts and insights into tissue cyst
organization based on the computed packing density [21••]. The ongoing expansion of the
capabilities in BradyCount 2.0 (Patwardhan and Sinai, in progress) will allow for more
refined data regarding quantifiable physiological criteria that can serve as inputs for datadriven computational models.
The clinical management of toxoplasmosis relies on the targeting of actively growing
tachyzoites [85, 86]. The primary drug combination targets folate metabolism on account of
the synergizing activities of pyrimethamine and sulfadiazine targeting dihydrofolate
reductase (DHFR) and dihydropterate synthase (DHPS), respectively [87]. Tissue cysts and
bradyzoites within them appear refractory to these antifolate drugs likely due to the low level
of DNA synthesis in the overall cyst population. The direct of demonstration of active
bradyzoite replication within in vivo tissue cysts [21••] suggests that this subpopulation of
bradyzoites should be susceptible. Just such an effect on bradyzoites is suggested by the
reduction of genome equivalents in the presence of Pyr/Sulfa in vivo using quantitative PCR
in infected brain samples [88].
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The earliest indication of drug capable of reducing the tissue cyst burden was observed in
the case of atovaquone [89–91]. This drug targets mitochondrial respiration at the level of
the cytochrome bc1complex [92]. More recently, the endochin-like quinolones, which also
target mitochondrial respiration were found to eliminate tissue cysts at between 76 and 88 %
of the control, levels far greater than those achieved with atovaquone [93••]. That
mitochondrial respiration targeting drugs appear to be effective suggests that mitochondrial
respiration must play a role in the maintenance of the chronic state thereby providing a
measurable physiological parameter for analysis. Other classes of drugs including
guanabenz, an FDA-approved drug targeting translational control through eIF2α [94], both
reduce the number of cysts formed when administered during the acute phase while also
promoting a reduction in the cyst burden during the chronic phase [95•]. Finally, a recently
developed inhibitor of the calcium-dependent protein kinase 1 (TgCDPK1) has also shown
promise in reducing the cyst burden [96•] by levels similar to what was observed with the
endochin-like quinolones [93••]. Importantly, unlike the encochin-like quinolones [93••], the
TgCDPK1-directed compounds are effective with oral administration [96•]. Furthermore, the
bradyzoite specific lethality associated with the TgCDPK2 knock-out [42••] presents this
kinase and amylopectin metabolism as a legitimate drug target.
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These recent developments, identifying multiple potential druggable targets coupled with an
emerging appreciation for bradyzoite replication and physiology, point toward a new phase
in the development of drugs targeting chronic toxoplasmosis.

Conclusions

Author Manuscript

A convergence of recent studies directly addressing the progression of chronic
toxoplasmosis in vivo, advances in the neurobiology of infection, and the identification of
new and effective drug targets presents new opportunities to understand this poorly studied
though critical life cycle stage of the parasite. Thus, the study of tissue cyst and bradyzoite
biology is emerging from the shadows where the area was treated largely as black box. The
field is poised to exploit new technological developments in parasite molecular and cell
biology to take on challenging questions at a level of sophistication that was unimaginable
even a few years ago. Understanding the basis of bradyzoite physiology and metabolism in
the context of both the immune competent and immune suppressed host will accelerate the
development of much needed therapies.

Acknowledgments
Preparation of this article was supported in part by NIH/NIAID R21AI122894 awarded to APS and IDeA award
from NIH/ NIGMS 5P30GM110787 (COBRE for the Center for Molecular Medicine. PI Louis B Hersh, University
of Kentucky) project awarded jointly to APS and MSG.

References
Papers of particular interest, published recently, have been highlighted as:
• Of importance

Author Manuscript

•• Of major importance

Author Manuscript

1. Dubey JP. Advances in the life cycle of Toxoplasma gondii. Int J Parasitol. 1998; 28(7):1019–24.
[PubMed: 9724872]
2. Hill D, Dubey JP. Toxoplasma gondii: transmission, diagnosis and prevention. Clin Microbiol Infect.
2002; 8(10):634–40. [PubMed: 12390281]
3. Dubey JP, Lindsay DS, Speer CA. Structures of Toxoplasma gondii tachyzoites, bradyzoites, and
sporozoites and biology and development of tissue cysts. Clin Microbiol Rev. 1998; 11(2):267–99.
[PubMed: 9564564]
4. Dubey JP, Jones JL. Toxoplasma gondii infection in humans and animals in the United States. Int J
Parasitol. 2008; 38(11):1257–78. [PubMed: 18508057]
5. Chew WK, Wah MJ, Ambu S, Segarra I. Toxoplasma gondii: determination of the onset of chronic
infection in mice and the in vitro reactivation of brain cysts. Exp Parasitol. 2012; 130(1):22–5.
[PubMed: 22027550]
6. Israelski DM, Chmiel JS, Poggensee L, Phair JP, Remington JS. Prevalence of Toxoplasma infection
in a cohort of homosexual men at risk of AIDS and toxoplasmic encephalitis. J Acquir Immune
Defic Syndr. 1993; 6(4):414–8. [PubMed: 8455146]
7. Nath A, Sinai AP. Cerebral Toxoplasmosis. Curr Treat Options Neurol. 2003; 5(1):3–12. [PubMed:
12521559]
8. Tenter AM, Heckeroth AR, Weiss LM. Toxoplasma gondii: from animals to humans. Int J Parasitol.
2000; 30(12–13):1217–58. [PubMed: 11113252]

Curr Clin Microbiol Rep. Author manuscript; available in PMC 2017 December 01.

Sinai et al.

Page 11

Author Manuscript
Author Manuscript
Author Manuscript
Author Manuscript

9. Ferguson DJ. Use of molecular and ultrastructural markers to evaluate stage conversion of
Toxoplasma gondii in both the intermediate and definitive host. Int J Parasitol. 2004; 34(3):347–60.
[PubMed: 15003495]
10. Ferguson DJ, Graham DI, Hutchison WM. Pathological changes in the brains of mice infected with
Toxoplasma gondii: a histological, immunocytochemical and ultrastructural study. Int J Exp
Pathol. 1991; 72(4):463–74. [PubMed: 1883744]
11. Ferguson DJ, Hutchison WM. An ultrastructural study of the early development and tissue cyst
formation of Toxoplasma gondii in the brains of mice. Parasitol Res. 1987; 73(6):483–91.
[PubMed: 3422976]
12. Fortier B, Coignard-Chatain C, Soete M, Dubremetz JF. Structure and biology of Toxoplasma
gondii bradyzoites. C R Seances Soc Biol Fil. 1996; 190(4):385–94. [PubMed: 8952889]
13. Sims TA, Hay J, Talbot IC. Ultrastructural immunocytochemistry of the intact tissue cyst of
Toxoplasma in the brains of mice with congenital toxoplasmosis. Ann Trop Med Parasitol. 1990;
84(2):141–7. [PubMed: 2383094]
14. Dzierszinski F, Nishi M, Ouko L, Roos DS. Dynamics of Toxoplasma gondii differentiation.
Eukaryotic Cell. 2004; 3(4):992–1003. [PubMed: 15302832]
15. Singh U, Brewer JL, Boothroyd JC. Genetic analysis of tachyzoite to bradyzoite differentiation
mutants in Toxoplasma gondii reveals a hierarchy of gene induction. Mol Microbiol. 2002; 44(3):
721–33. [PubMed: 11994153]
16. White MW, Radke JR, Radke JB. Toxoplasma development-turn the switch on or off? Cellular
microbiology. 2014
17. Fritz HM, Buchholz KR, Chen X, Durbin-Johnson B, Rocke DM, Conrad PA, et al. Transcriptomic
analysis of toxoplasma development reveals many novel functions and structures specific to
sporozoites and oocysts. PLoS One. 2012; 7(2):e29998. [PubMed: 22347997]
18•. Pittman KJ, Aliota MT, Knoll LJ. Dual transcriptional profiling of mice and Toxoplasma gondii
during acute and chronic infection. BMC Genomics. 2014; 15:806. The use of RNASeq to
simultaneously establish the interplay between parasite and host at the level of gene expression
hold the promise of dissecting the complex interplay during different stages of the chronic
infection. [PubMed: 25240600]
19. Knoll, LJ., Tomita, T., Weiss, LM. Bradyzoite Development. In: Weiss, LM., Kim, K., editors.
Toxoplasma gondii The Model Apicomplexan: Perspectives and Methods. 2. London, United
Kingdom: Academic Press (Elsevier); 2014. p. 521-49.
20. Pittman KJ, Knoll LJ. Long-Term Relationships: the Complicated Interplay between the Host and
the Developmental Stages of Toxoplasma gondii during Acute and Chronic Infections. Microbiol
Mole Biol Rev : MMBR. 2015; 79(4):387–401.
21••. Watts E, Zhao Y, Dhara A, Eller B, Patwardhan A, Sinai AP. Novel Approaches Reveal that
Toxoplasma gondii Bradyzoites within Tissue Cysts Are Dynamic and Replicating Entities In
Vivo. mBio. 2015; 6(5):e01155–15. This work conclusively dispels the notion that parasite
replication does not occur during the chronic phase of infection. The work reveals that
bradyzoites within cysts are not uniform and that the properties of tissue cysts vary during the
course of infection. Quantification of bradyzoites within tissue cysts vastly reveals an
unappreciated level of complexity in the progression of chronic toxoplasmosis. [PubMed:
26350965]
22. Skariah S, McIntyre MK, Mordue DG. Toxoplasma gondii: determinants of tachyzoite to
bradyzoite conversion. Parasitol Res. 2010; 107(2):253–60. [PubMed: 20514494]
23. Lemgruber L, Lupetti P, Martins-Duarte ES, De Souza W, Vommaro RC. The organization of the
wall filaments and characterization of the matrix structures of Toxoplasma gondii cyst form. Cell
Microbiol. 2011; 13(12):1920–32. [PubMed: 21899696]
24. Ferguson DJ, Huskinson-Mark J, Araujo FG, Remington JS. A morphological study of chronic
cerebral toxoplasmosis in mice: comparison of four different strains of Toxoplasma gondii.
Parasitol Res. 1994; 80(6):493–501. [PubMed: 7808999]
25. Scholtyseck E, Mehlhorn H, Muller BE. Fine structure of cyst and cyst wall of Sarcocystis tenella,
Besnoitia jellisoni, Frenkelia sp. and Toxoplasma gondii. J Protozool. 1974; 21(2):284–94.
[PubMed: 4209540]

Curr Clin Microbiol Rep. Author manuscript; available in PMC 2017 December 01.

Sinai et al.

Page 12

Author Manuscript
Author Manuscript
Author Manuscript
Author Manuscript

26. van der Zypen E, Piekarski G. On the ultrastructure of the Toxoplasma gondii cyst wall in the brain
of the white mouse. Z Parasitenkd. 1966; 28(1):45–59. [PubMed: 5982315]
27. de Carvalho L, Souto-Padron T, de Souza W. Localization of lectin-binding sites and sugar-binding
proteins in tachyzoites of Toxoplasma gondii. J Parasitol. 1991; 77(1):156–61. [PubMed:
1992086]
28. Fauquenoy S, Morelle W, Hovasse A, Bednarczyk A, Slomianny C, Schaeffer C, et al. Proteomics
and glycomics analyses of N-glycosylated structures involved in Toxoplasma gondii–host cell
interactions. Mol Cell Proteomics. 2008; 7(5):891–910. [PubMed: 18187410]
29. Cummings, RD., Etzler, ME. Antibodies and Lectins in Glycan Analysis. In: Varki, A.Cummings,
RD.Esko, JD.Freeze, HH.Stanley, P.Bertozzo, CR., et al., editors. Essentials of Glycobiology. 2.
Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 2008. p. 633-49.
30. Derouin F, Beauvais B, Lariviere M, Guillot J. Binding of fluorescein-labelled lectins on
trophozoites and cysts of 3 strains of Toxoplasma gondii. C R Seances Soc Biol Fil. 1981; 175(6):
761–8. [PubMed: 6459820]
31. Sethi KK, Rahman A, Pelster B, Brandis H. Search for the presence of lectin-binding sites on
Toxoplasma gondii. J Parasitol. 1977; 63(6):1076–80. [PubMed: 592038]
32••. Tomita T, Bzik DJ, Ma YF, Fox BA, Markillie LM, Taylor RC, et al. The Toxoplasma gondii
Cyst Wall Protein CST1 Is Critical for Cyst Wall Integrity and Promotes Bradyzoite Persistence.
PLoS Pathog. 2013; 9(12):e1003823. Identification of the primary protein target responsible for
lectin lableling of the cyst wall also establishes TgCST1 as a key strutural element in the
mantaining cyst integrity. [PubMed: 24385904]
33. Tomita T, Tatsuki T, Yakubu R, Tu V, Ma YF, Weiss LM. Making home sweet and sturdy:
Toxoplasma gondii ppGalNAc-ts glycosylate in heirarchical order and confer cyst wall rigidity.
mBio. 2016 Submitted.
34•. Caffaro CE, Koshy AA, Liu L, Zeiner GM, Hirschberg CB, Boothroyd JC. A nucleotide sugar
transporter involved in glycosylation of the Toxoplasma tissue cyst wall is required for efficient
persistence of bradyzoites. PLoS Pathog. 2013; 9(5):e1003331. Confirms the central role for
glycoslylation in the maintenance of chronic toxoplasma infections. [PubMed: 23658519]
35•. Nazarova LA, Ochoa RJ, Jones KA, Morrissette NS, Prescher JA. Extracellular Toxoplasma
gondii tachyzoites metabolize and incorporate unnatural sugars into cellular proteins. Microbes
and infection/Institut Pasteur. 2016; 18(3):199–210. This technical advance is the first use of
chemical biology approaches to identify glycoproteins in Toxoplasma.
36. Bushkin GG, Ratner DM, Cui J, Banerjee S, Duraisingh MT, Jennings CV, et al. Suggestive
evidence for Darwinian Selection against asparagine-linked glycans of Plasmodium falciparum
and Toxoplasma gondii. Eukaryotic Cell. 2010; 9(2):228–41. [PubMed: 19783771]
37. Samuelson J, Robbins PW. Effects of N-glycan precursor length diversity on quality control of
protein folding and on protein glycosylation. Semin Cell Dev Biol. 2015; 41:121–8. [PubMed:
25475176]
38. Odenthal-Schnittler M, Tomavo S, Becker D, Dubremetz JF, Schwarz RT. Evidence for N-linked
glycosylation in Toxoplasma gondii. Biochem J. 1993; 291(Pt 3):713–21. [PubMed: 8489499]
39. Coppin A, Dzierszinski F, Legrand S, Mortuaire M, Ferguson D, Tomavo S. Developmentally
regulated biosynthesis of carbohydrate and storage polysaccharide during differentiation and tissue
cyst formation in Toxoplasma gondii. Biochimie. 2003; 85(3–4):353–61. [PubMed: 12770773]
40. Coppin A, Varre JS, Lienard L, Dauvillee D, Guerardel Y, Soyer-Gobillard MO, et al. Evolution of
plant-like crystalline storage polysaccharide in the protozoan parasite Toxoplasma gondii argues
for a red alga ancestry. J Mol Evol. 2005; 60(2):257–67. [PubMed: 15785854]
41. Guerardel Y, Leleu D, Coppin A, Lienard L, Slomianny C, Strecker G, et al. Amylopectin
biogenesis and characterization in the protozoan parasite Toxoplasma gondii, the intracellular
development of which is restricted in the HepG2 cell line. Microbes Infect/Institut Pasteur. 2005;
7(1):41–8.
42••. Uboldi AD, McCoy JM, Blume M, Gerlic M, Ferguson DJ, Dagley LF, et al. Regulation of
Starch Stores by a Ca(2+)-Dependent Protein Kinase Is Essential for Viable Cyst Development in
Toxoplasma gondii. Cell Host Microbe. 2015; 18(6):670–81. This work demonstrates that the
dysregualtion of amylopectin metabolism is lethal to bradyzoites and promotes the clearance of

Curr Clin Microbiol Rep. Author manuscript; available in PMC 2017 December 01.

Sinai et al.

Page 13

Author Manuscript
Author Manuscript
Author Manuscript
Author Manuscript

tissue cysts. It demonstrates that amylopectin must play a role in bradyzoites rather than serve
merely as an energy storage system for rapid growth following reactivation. This presents
amylopecting metabolism as a potential drug target in chronic toxoplasmosis. [PubMed:
26651943]
43. Dubey JP. Distribution of tissue cysts in organs of rats fed Toxoplasma gondii oocysts. J Parasitol.
1997; 83(4):755–7. [PubMed: 9267423]
44. Scallan E, Hoekstra RM, Mahon BE, Jones TF, Griffin PM. An assessment of the human health
impact of seven leading foodborne pathogens in the United States using disability adjusted life
years. Epidemiol Infect. 2015; 143(13):2795–804. [PubMed: 25633631]
45. Tonino P, Finol HJ, Marquez A. Skeletal muscle pathology in mice experimentally infected with
Toxoplasma gondii. J Submicrosc Cytol Pathol. 1996; 28(4):521–6. [PubMed: 8933735]
46. da Ferreira-da-Silva MF, Takacs AC, Barbosa HS, Gross U, Luder CG. Primary skeletal muscle
cells trigger spontaneous Toxoplasma gondii tachyzoite-to-bradyzoite conversion at higher rates
than fibroblasts. Int J Med Microbiol: IJMM. 2009; 299(5):381–8. [PubMed: 19097936]
47. Guimaraes EV, de Carvalho L, Barbosa HS. Primary culture of skeletal muscle cells as a model for
studies of Toxoplasma gondii cystogenesis. J Parasitol. 2008; 94(1):72–83. [PubMed: 18372624]
48. Swierzy IJ, Luder CG. Withdrawal of skeletal muscle cells from cell cycle progression triggers
differentiation of Toxoplasma gondii towards the bradyzoite stage. Cell Microbiol. 2015; 17(1):2–
17. [PubMed: 25131712]
49. Cornelissen AW, Overdulve JP, Hoenderboom JM. Separation of Isospora (Toxoplasma) gondii
cysts and cystozoites from mouse brain tissue by continuous density-gradient centrifugation.
Parasitology. 1981; 83(Pt 1):103–8. [PubMed: 6267543]
50. Dubey JP. Comparative infectivity of Toxoplasma gondii bradyzoites in rats and mice. J Parasitol.
1998; 84(6):1279–82. [PubMed: 9920331]
51••. Dubey JP, Ferreira LR, Alsaad M, Verma SK, Alves DA, Holland GN, et al. Experimental
Toxoplasmosis in Rats Induced Orally with Eleven Strains of Toxoplasma gondii of Seven
Genotypes: Tissue Tropism, Tissue Cyst Size, Neural Lesions, Tissue Cyst Rupture without
Reactivation, and Ocular Lesions. PloS One. 2016; 11(5):e0156255. This comprehensive study
and review of the literature in rats and mice presents the simialrites and differences in these
model rodent systems. Given the body of behavioral work in rats, the revisiting of the rat
infection model will be useful for the integration of future behavioral studies. [PubMed:
27228262]
52. Van Der Waaij D. Formation, growth and multiplication of Toxoplasma gondii cysts in mouse
brain. Trop Georg Med. 1959; 11:345–60.
53. Sullivan AM, Zhao X, Suzuki Y, Ochiai E, Crutcher S, Gilchrist MA. Evidence for finely-regulated
asynchronous growth of Toxoplasma gondii cysts based on data-driven model selection. PLoS
Comput Biol. 2013; 9(11):e1003283. [PubMed: 24244117]
54. Hooshyar H, Rostamkhani P, Arbabi M. Study on growth of Toxoplasma gondii tissue cyst in
laboratory mouse. Jundishpur J Microbiol. 2009; 2(4):140–3.
55. Weiss LM, Kim K. The development and biology of bradyzoites of Toxoplasma gondii. Front
Biosci. 2000; 5:D391–405. [PubMed: 10762601]
56. Anderson-White BR, Ivey FD, Cheng K, Szatanek T, Lorestani A, Beckers CJ, et al. A family of
intermediate filament-like proteins is sequentially assembled into the cytoskeleton of Toxoplasma
gondii. Cell Microbiol. 2011; 13(1):18–31. [PubMed: 20698859]
57. Elsheikha HM, Busselberg D, Zhu XQ. The known and missing links between Toxoplasma gondii
and schizophrenia. Metab Brain Dis. 2016; 31(4):749–59. [PubMed: 27041387]
58. Sutterland AL, Fond G, Kuin A, Koeter MW, Lutter R, van Gool T, et al. Beyond the association.
Toxoplasma gondii in schizophrenia, bipolar disorder, and addiction: systematic review and metaanalysis. Acta psychiatrica Scandinavica. 2015
59. Ngoungou EB, Bhalla D, Nzoghe A, Darde ML, Preux PM. Toxoplasmosis and epilepsy–
systematic review and meta analysis. PLoS Negl Trop Dis. 2015; 9(2):e0003525. [PubMed:
25695802]

Curr Clin Microbiol Rep. Author manuscript; available in PMC 2017 December 01.

Sinai et al.

Page 14

Author Manuscript
Author Manuscript
Author Manuscript
Author Manuscript

60. Mahami-Oskouei M, Hamidi F, Talebi M, Farhoudi M, Taheraghdam AA, Kazemi T, et al.
Toxoplasmosis and Alzheimer: can Toxoplasma gondii really be introduced as a risk factor in
etiology of Alzheimer? Parasitol Res. 2016
61. Mohle L, Israel N, Paarmann K, Krohn M, Pietkiewicz S, Muller A, et al. Chronic Toxoplasma
gondii infection enhances beta-amyloid phagocytosis and clearance by recruited monocytes. Acta
Neuropathol Commun. 2016; 4:25. [PubMed: 26984535]
62. Prandota J. Possible link between Toxoplasma gondii and the anosmia associated with
neurodegenerative diseases. Am J Alzheimer’s Dis Other Dementias. 2014; 29(3):205–14.
63. McConkey GA, Martin HL, Bristow GC, Webster JP. Toxoplasma gondii infection and behaviour location, location, location? J Exp Biol. 2013; 216(Pt 1):113–9. [PubMed: 23225873]
64. Webster JP, Kaushik M, Bristow GC, McConkey GA. Toxoplasma gondii infection, from predation
to schizophrenia: can animal behaviour help us understand human behaviour? J Exp Biol. 2013;
216(Pt 1):99–112. [PubMed: 23225872]
65. Flegr J. Effects of toxoplasma on human behavior. Schizophr Bull. 2007; 33(3):757–60. [PubMed:
17218612]
66. Parlog A, Schluter D, Dunay IR. Toxoplasma gondii-induced neuronal alterations. Parasite
Immunol. 2015; 37(3):159–70. [PubMed: 25376390]
67. Vyas A. Mechanisms of Host Behavioral Change in Toxoplasma gondii Rodent Association. PLoS
Pathog. 2015; 11(7):e1004935. [PubMed: 26203656]
68. Gatkowska J, Wieczorek M, Dziadek B, Dzitko K, Dlugonska H. Behavioral changes in mice
caused by Toxoplasma gondii invasion of brain. Parasitol Res. 2012; 111(1):53–8. [PubMed:
22223035]
69. Berenreiterova M, Flegr J, Kubena AA, Nemec P. The distribution of Toxoplasma gondii cysts in
the brain of a mouse with latent toxoplasmosis: implications for the behavioral manipulation
hypothesis. PLoS One. 2011; 6(12):e28925. [PubMed: 22194951]
70. Afonso C, Paixao VB, Costa RM. Chronic Toxoplasma infection modifies the structure and the risk
of host behavior. PLoS One. 2012; 7(3):e32489. [PubMed: 22431975]
71. Di Cristina M, Marocco D, Galizi R, Proietti C, Spaccapelo R, Crisanti A. Temporal and spatial
distribution of Toxoplasma gondii differentiation into Bradyzoites and tissue cyst formation in
vivo. Infect Immun. 2008; 76(8):3491–501. [PubMed: 18505811]
72. Cabral CM, Tuladhar S, Dietrich HK, Nguyen E, MacDonald WR, Trivedi T, et al. Neurons are the
Primary Target Cell for the Brain-Tropic Intracellular Parasite Toxoplasma gondii. PLoS Pathog.
2016; 12(2):e1005447. [PubMed: 26895155]
73. Hermes G, Ajioka JW, Kelly KA, Mui E, Roberts F, Kasza K, et al. Neurological and behavioral
abnormalities, ventricular dilatation, altered cellular functions, inflammation, and neuronal injury
in brains of mice due to common, persistent, parasitic infection. J Neuroinflammation. 2008; 5:48.
[PubMed: 18947414]
74. Melzer TC, Cranston HJ, Weiss LM, Halonen SK. Host Cell Preference of Toxoplasma gondii
Cysts in Murine Brain: A Confocal Study. J Neuroparasitology. 2010:1.
75. Sibley LD, Qiu W, Fentress S, Taylor SJ, Khan A, Hui R. Forward genetics in Toxoplasma gondii
reveals a family of rhoptry kinases that mediates pathogenesis. Eukaryotic Cell. 2009; 8(8):1085–
93. [PubMed: 19465561]
76. Koshy AA, Dietrich HK, Christian DA, Melehani JH, Shastri AJ, Hunter CA, et al. Toxoplasma
co-opts host cells it does not invade. PLoS Pathog. 2012; 8(7):e1002825. [PubMed: 22910631]
77. Boothroyd JC, Dubremetz JF. Kiss and spit: the dual roles of Toxoplasma rhoptries. Nat Rev
Microbiol. 2008; 6(1):79–88. [PubMed: 18059289]
78. Rangel-Barajas C, Coronel I, Floran B. Dopamine Receptors and Neurodegeneration. Aging Dis.
2015; 6(5):349–68. [PubMed: 26425390]
79•. Gaskell EA, Smith JE, Pinney JW, Westhead DR, McConkey GA. A unique dual activity amino
acid hydroxylase in Toxoplasma gondii. PloS One. 2009; 4(3):e4801. The potential for direct
inteference with dopamine metabolism establishes a potential mechanism for parasite mediated
modulation of CNS function. [PubMed: 19277211]

Curr Clin Microbiol Rep. Author manuscript; available in PMC 2017 December 01.

Sinai et al.

Page 15

Author Manuscript
Author Manuscript
Author Manuscript
Author Manuscript

80. Prandovszky E, Gaskell E, Martin H, Dubey JP, Webster JP, McConkey GA. The neurotropic
parasite Toxoplasma gondii increases dopamine metabolism. PLoS One. 2011; 6(9):e23866.
[PubMed: 21957440]
81•. Brooks JM, Carrillo GL, Su J, Lindsay DS, Fox MA, Blader IJ. Toxoplasma gondii Infections
Alter GABAergic Synapses and Signaling in the Central Nervous System. mBio. 2015;
6(6):e01428–15. Exposition of infection mediated neurological changes and their association
with structural changes in GABAergic responses begins to examine the basis for potential
paasrite driven changes during chronic infection. [PubMed: 26507232]
82••. David CN, Frias ES, Szu JI, Vieira PA, Hubbard JA, Lovelace J, et al. GLT-1-Dependent
Disruption of CNS Glutamate Homeostasis and Neuronal Function by the Protozoan Parasite
Toxoplasma gondii. PLoS Pathogens. 2016; 12(6):e1005643. This study is important in that it not
only describes the changes instituted in the infected mouse brain but also provides a mechansitic
framework supported by biochemical data in addition to quantitative moprhometry to document
infection-related changes in the brain. [PubMed: 27281462]
83. Lau A, Tymianski M. Glutamate receptors, neurotoxicity and neurodegeneration. Pflugers Arch Eur J Physiol. 2010; 460(2):525–42. [PubMed: 20229265]
84. Hunter CA, Sibley LD. Modulation of innate immunity by Toxoplasma gondii virulence effectors.
Nat Rev Microbiol. 2012; 10(11):766–78. [PubMed: 23070557]
85. Kaye A. Toxoplasmosis: diagnosis, treatment, and prevention in congenitally exposed infants. J
Pediatr Health Care. 2011; 25(6):355–64. [PubMed: 22018426]
86. Rajapakse S, Chrishan Shivanthan M, Samaranayake N, Rodrigo C, Deepika FS. Antibiotics for
human toxoplasmosis: a systematic review of randomized trials. Pathog Glob Health. 2013;
107(4):162–9. [PubMed: 23816507]
87. Hyde JE. Targeting purine and pyrimidine metabolism in human apicomplexan parasites. Curr
Drug Targets. 2007; 8(1):31–47. [PubMed: 17266529]
88. Notarangelo FM, Wilson EH, Horning KJ, Thomas MA, Harris TH, Fang Q, et al. Evaluation of
kynurenine pathway metabolism in Toxoplasma gondii-infected mice: implications for
schizophrenia. Schizophr Res. 2014; 152(1):261–7. [PubMed: 24345671]
89. Araujo FG, Huskinson-Mark J, Gutteridge WE, Remington JS. In vitro and in vivo activities of the
hydroxynaphthoquinone 566C80 against the cyst form of Toxoplasma gondii. Antimicrob Agents
Chemother. 1992; 36(2):326–30. [PubMed: 1605598]
90. Ferguson DJ, Huskinson-Mark J, Araujo FG, Remington JS. An ultrastructural study of the effect
of treatment with atovaquone in brains of mice chronically infected with the ME49 strain of
Toxoplasma gondii. Int J Exp Pathol. 1994; 75(2):111–6. [PubMed: 8199003]
91. Huskinson-Mark J, Araujo FG, Remington JS. Evaluation of the effect of drugs on the cyst form of
Toxoplasma gondii. J Infect Dis. 1991; 164(1):170–1. [PubMed: 1647421]
92. McFadden DC, Boothroyd JC. Cytochrome b mutation identified in a decoquinate-resistant mutant
of Toxoplasma gondii. J Eukaryot Microbiol. 1999; 46(5):81S–2S. [PubMed: 10519259]
93••. Doggett JS, Nilsen A, Forquer I, Wegmann KW, Jones-Brando L, Yolken RH, et al. Endochinlike quinolones are highly efficacious against acute and latent experimental toxoplasmosis. Proc
Nat Acad Sci USA. 2012; 109(39):15936–41. The first family of drugs that exhibit signficant
efficacy in the clearance of tissue cysts in the mouse model. The study also provides valuable
insights into the metabolic and physiological state of bradyzoites supporting a view for their
being more active than previously considered. [PubMed: 23019377]
94. Zhang M, Joyce BR, Sullivan WJ Jr, Nussenzweig V. Translational control in Plasmodium and
toxoplasma parasites. Eukaryotic Cell. 2013; 12(2):161–7. [PubMed: 23243065]
95•. Benmerzouga I, Checkley LA, Ferdig MT, Arrizabalaga G, Wek RC, Sullivan WJ Jr. Guanabenz
repurposed as an antiparasitic with activity against acute and latent toxoplasmosis. Antimicrob
Agents Chemother. 2015; 59(11):6939–45. The establishment of translational control as a
potential target for drug dvelopment. The study also highlights the utility of drug repurposing as
a strategy to streamline drug dvelopment for what may be considered orphan infections.
[PubMed: 26303803]
96•. Vidadala RS, Rivas KL, Ojo KK, Hulverson MA, Zambriski JA, Bruzual I, et al. Development of
an Orally Available and Central Nervous System (CNS) Penetrant Toxoplasma gondii Calcium-

Curr Clin Microbiol Rep. Author manuscript; available in PMC 2017 December 01.

Sinai et al.

Page 16

Author Manuscript

Dependent Protein Kinase 1 (TgCDPK1) Inhibitor with Minimal Human Ether-a-go-go-Related
Gene (hERG) Activity for the Treatment of Toxoplasmosis. J Med Chem. 2016; 59(13):6531–46.
Identification of TgCDPK’s as targets for drug development against chronic toxoplasma
infections presents an additional and legitimate target. The development of an orally available
compound holds promise for treatment. [PubMed: 27309760]

Author Manuscript
Author Manuscript
Author Manuscript
Curr Clin Microbiol Rep. Author manuscript; available in PMC 2017 December 01.

Sinai et al.

Page 17

Author Manuscript
Fig. 1.

Author Manuscript

Distribution of key glycans in tissue cysts. A distinguishing feature of Toxoplasma gondii
tissue cysts is the high level of glycosylation. Left panel lectin staining with FITCconjugated Dolichos biflorus (DBA-recognizing GalNAc) lectin labels the tissue cyst wall
and the intra-cyst matrix (green). In contrast, Concanavalin A (ConA-recognizing mannose
and glucose, and an indicator of N-linked glycosylation) selectively stains structures within
the bradyzoites and in the matrix (red) but is excluded from the tissue cyst wall (merge).
Right panel the distribution of amylopectin granules within bradyzoites detected using
Schiff reagent (red) overlaid on a differential interference contrast of a purified tissue cyst
reveals an uneven distribution of amylopectin within the tissue cyst with clusters of
bradyzoites exhibiting high levels of amylopectin (outlined in green) adjacent to areas with
low amylopectin levels (outlined in yellow)
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Fig. 2.
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Evidence of replication and patterns of replication within tissue cysts. Tissue cysts and the
bradyzoites within them have been viewed as dormant non-replicative entities. Replication
by endodyogeny and cytokinesis in toxoplasma can be detected using antibodies against
components of the inner membrane complex (IMC) including TgIMC3. Top panel the
intensity of TgIMC3 is highest in developing daughter parasites and recently emerged
parasites. Following emergence, the TgIMC3 signal loses intensity and can thus serve as a
marker for the recency of replication. Bottom panel actively replicating bradyzoites within
tissue cysts can be detected based on the level of TgIMC3 labeling. Evidence for sporadic
replication (left panel, arrowheads), clustered replication (outlined in yellow) with a region
where replication is not occurring (outlined in red) are seen in most cases. In several cases,
highly synchronized replication whereby all the bradyzoites within tissue cyst were dividing
at the same time is observed. Together, these findings suggest that the tissue cysts are
dynamic entities containing replication competent bradyzoites

Author Manuscript
Curr Clin Microbiol Rep. Author manuscript; available in PMC 2017 December 01.

